CenterBook Partners LP Purchases New Shares in Sionna Therapeutics, Inc. (NASDAQ:SION)

Key Points

• CenterBook Partners LP invested approximately $1,195,000 in Sionna Therapeutics by acquiring 114,284 shares, giving them about 0.26% ownership of the company.
• Recently, several institutional investors, including Jennison Associates LLC and TD Asset Management Inc, also established new stakes in Sionna Therapeutics, reflecting growing interest in the company.
• Sionna Therapeutics reported a quarterly loss of ($0.62) EPS, underperforming against analysts' estimates of ($0.45), and has seen its stock price fluctuate between a 12-month low of $7.26 and a high of $25.19.

CenterBook Partners LP purchased a new stake in Sionna Therapeutics, Inc. (NASDAQ:SION - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 114,284 shares of the company's stock, valued at approximately $1,195,000. CenterBook Partners LP owned about 0.26% of Sionna Therapeutics at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of SION. Jennison Associates LLC purchased a new stake in Sionna Therapeutics in the 1st quarter valued at $8,995,000. TD Asset Management Inc acquired a new position in shares of Sionna Therapeutics in the first quarter valued at approximately $579,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in shares of Sionna Therapeutics in the first quarter valued at approximately $676,000.

Sionna Therapeutics Trading Up 1.8%

NASDAQ:SION opened at $17.28 on Friday. The company has a 50 day moving average of $17.47. Sionna Therapeutics, Inc. has a 12-month low of $7.26 and a 12-month high of $25.19.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.62) earnings per share for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.17).

Insider Buying and Selling at Sionna Therapeutics

In related news, major shareholder Tpg Gp A, Llc purchased 60,000 shares of the stock in a transaction dated Friday, June 27th. The shares were acquired at an average cost of $15.84 per share, with a total value of $950,400.00. Following the purchase, the insider directly owned 6,744,962 shares in the company, valued at $106,840,198.08. This trade represents a 0.90% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 3.90% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Separately, Wall Street Zen lowered Sionna Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd.

Sionna Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.

Want to see what other hedge funds are holding SION? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sionna Therapeutics, Inc. (NASDAQ:SION - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.